Is there adequate evidence for the use of PARPi in combination with ARSI for BRCA+/HRR mutated mCRPC as compared to sequential therapy?

When treating BRCA+/HRR mutated mCRPC, what primarily guides your decision to use PARPi and ARSI in combination vs in sequence?

• PFS benefit from combination therapy leads me to use PARPi/ARSI combinations for most patients
• Lack of mature OS data leads me to use sequential monotherapy for most patients pending further results
• Toxicity concerns with combination therapy leads me to use sequential monotherapy
• Cost concerns with combination therapy leads me to use sequential monotherapy
• Type of genomic alteration: combinations only for BRCA mutated specifically
• Type of genomic alteration: combinations for non-BRCA HRR mutated specifically
• Patient preference leads me to select PARPi/ARSI combinations for most patients
• Patient preference leads me to use sequential monotherapy for most patients
• Other